PA-1-STK Ovarian Carcinoma Vaccine

A cell-based cancer vaccine with potential antineoplastic activity. PA-1-STK ovarian carcinoma vaccine is produced by transducing the ovarian cancer cell line, PA-1, with the herpes simplex thymidine kinase (HSV-tk) gene, resulting in a cell line, PA-1-STK, that permanently expresses the HSV tk gene. Upon transfection into malignant cells, this vaccine is capable of sensitizing tumor cells in response to an antiviral drug such as ganciclovir, which is readily phosphorylated by the TK enzyme to its active form. Administration of ganciclovir following PA-1 STK transfection results in enhanced cytotoxicity of the transfected tumor cells. Additionally, adjacent non-transfected cells are also killed by the activated antiviral drug, a phenomenon referred to as the bystander effect that occurs with this type of suicide-gene transfer technique. (NCI Thesaurus)

YOU MAY ALSO LIKE

PA

A health professional who is licensed to do certain medical procedures under the guidance of a doctor. A PA may take…

p70S6K/Akt Inhibitor MSC2363318A

An orally available inhibitor of the serine/threonine protein kinases ribosomal protein S6 Kinase (p70S6K) and Akt (protein kinase B), with potential antineoplastic…

p70S6K Inhibitor LY2584702

An orally available inhibitor of p70S6K signaling, with potential antineoplastic activity. p70S6K inhibitor LY2584702 inhibits ribosomal protein S6 Kinase (p70S6K), and prevents…

p59-HCK

Encoded by the HCK proto-oncogene, HCK appears to be a SRC-family tyrosine kinase, expressed primarily in hematopoietic cells, especially of myeloid lineage…

p53/HDM2 Interaction Inhibitor CGM097

An orally bioavailable HDM2 (human homolog of double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, p53/HDM2 interaction inhibitor CGM097…

p53:264-272 Peptide

A synthetic peptide derived from the tumor suppressor protein p53 with potential use in cancer immunotherapy. p53:264-272 peptide consists of amino…